{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-103005","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2023-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.020173+00:00","generated_at":"2026-06-17T01:30:59.799678+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ikena presents preclinical data for IK-930 with TEAD1 selectivity and wider therapeutic window vs panTEAD","bullets":["IK-930 selectively inhibits TEAD1 with equivalent antitumor activity to panTEAD inhibitors but no renal toxicity in monkeys at any tested dose.","Average urinary protein-to-creatinine ratios and histopathology predicted a therapeutic index <1 for panTEAD vs broad window for IK-930.","IK-930 plus osimertinib delayed emergence of drug-tolerant persister cells in preclinical EGFR-mutant NSCLC models.","Phase 1 monotherapy dose escalation ongoing; initial monotherapy clinical data expected in 2H 2023.","Cash >$155M as of filing; runway into 2025; partnered IK-175 with BMS potentially $50M opt-in fees by early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-103005","json":"https://secwatch.observer/filing/0001193125-23-103005.json","markdown":"https://secwatch.observer/filing/0001193125-23-103005.md","text":"https://secwatch.observer/filing/0001193125-23-103005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523103005/0001193125-23-103005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523103005/d460401d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:30:59.799678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}